Idorsia Ltd (LON:0RQE)
3.853
-0.078 (-1.99%)
At close: Feb 12, 2026
Idorsia Revenue
Idorsia had revenue of 41.49M CHF in the quarter ending September 30, 2025, with 58.35% growth. This brings the company's revenue in the last twelve months to 232.51M, up 213.69% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
232.51M CHF
Revenue Growth
+213.69%
P/S Ratio
4.27
Revenue / Employee
357.71K CHF
Employees
650
Market Cap
925.47M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
| Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
| Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
| Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
| Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.80M |
| Oxford Nanopore Technologies | 204.69M |
| Oxford Biomedica | 151.21M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| SkinBioTherapeutics | 4.64M |
| 4basebio | 1.78M |